Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Quinazoline. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN103130811B reveals efficient cascade synthesis for pharmaceutical intermediates. This method offers significant cost reduction and supply chain reliability for global buyers.
Novel synthesis of Erlotinib HCl via 3,4-dihydroxybenzaldehyde avoids demethylation steps, offering cost-effective industrial scale-up for pharmaceutical intermediates.
Novel one-pot synthesis of dihydropyrroloquinazoline spiroindoles with anticancer activity. Efficient Ru-catalyzed route offers cost reduction and supply chain reliability for pharma manufacturing.
Advanced synthesis of Gefitinib intermediates via CN102146060A. Eco-friendly route eliminates halogenating agents, ensuring high purity and cost reduction in API manufacturing.
Efficient Cu(OTf)2 catalyzed synthesis of quinazoline-4-amines via green one-pot tandem reaction. Reliable API intermediate supplier offering cost reduction.
Novel patent CN117209503B reveals efficient synthesis route for antioxidant intermediates. Reduces steps and cost for pharmaceutical manufacturing supply chains.
Patent CN102675222B reveals copper-catalyzed quinazoline synthesis. Offers cost reduction and supply chain reliability for pharmaceutical intermediates manufacturing.
Novel C-H activation method for spiro quinazolinones offers high yield and scalability for reliable pharmaceutical intermediate supply chains.
Patent CN104610267A reveals catalyst-free synthesis for high-purity pyrazoloquinazoline derivatives, offering significant supply chain and cost advantages for pharmaceutical manufacturing.
Patent CN103288757A reveals a novel solid-acid catalyzed nitration route for key TKI intermediates, offering significant cost reduction and simplified supply chains for pharmaceutical manufacturers.
Patent CN102120731A reveals a novel, high-yield route for Gefitinib intermediates, offering significant cost reduction and simplified purification for pharmaceutical manufacturing.
Patent CN107216331B reveals efficient synthesis for tetrahydroquinazoline derivatives. Enables cost reduction and scalable supply for pharmaceutical intermediates manufacturing.
Patent CN105111217B reveals efficient copper-catalyzed one-pot synthesis. Delivers high-purity pharmaceutical intermediates with significant cost reduction and supply chain reliability.
Patent CN110003121A reveals a copper-catalyzed route for 3,4-dihydroquinazoline derivatives offering mild conditions and high purity for pharmaceutical intermediate manufacturing supply chains.
Patent CN105884698B reveals a Pd-catalyzed route for quinazolines. Offers high yield and scalable manufacturing for pharmaceutical intermediate suppliers globally.
Patent CN104045643A details water-phase copper catalysis for pyrazolo quinazoline. Offers cost reduction in pharmaceutical intermediate manufacturing and high purity.
Patent CN116375653A details a high enantioselective iridium-catalyzed method for chiral tetrahydroquinazoline derivatives, offering cost-effective API intermediate manufacturing solutions.
Novel metal-catalyzed route enhances purity and scalability for complex heterocycles, offering substantial cost reduction and supply chain reliability for global pharmaceutical manufacturing.
Patent CN110577520B reveals a green, high-yield route for 6-nitro-4-substituted amino quinazoline. Ideal for reliable API intermediate supply chains.
Patent CN105884698A reveals advanced Pd-catalyzed route offering high yields and streamlined supply chain for global pharmaceutical intermediate procurement strategies.